Filing summary
Entity identification: The supplied filing is MedTech Acquisition Corporation’s Form 10-K, not a TriSalus Life Sciences, Inc. filing. MedTech was a blank-check company seeking a business combination. The filing covers the fiscal year ended December 31, 2021 and was signed March 2, 2022.
Business context and reporting period
MedTech had no operating business and had not generated revenue. It was formed to complete a business combination, with a stated focus on U.S. healthcare businesses. On August 12, 2021, it agreed to combine with Memic Innovative Surgery Ltd., a medical-device company developing surgical robotics. The proposed transaction implied a $625 million enterprise value for Memic and included a planned $76.35 million PIPE investment. The transaction was not completed as of this filing.
Financial results and liquidity
| Metric | FY 2021 / December 31, 2021 | Comparable period |
|---|---|---|
| Revenue | None | None since inception |
| Net income (loss) | $4.77 million | $(0.71) million from September 11, 2020 inception through December 31, 2020 |
| General and administrative expenses | $3.04 million | $108,493 for the 2020 inception period |
| Interest income on trust assets | $63,997 | $3,298 for the 2020 inception period |
| Operating cash flow | $(1.74) million | $(677,599) for the 2020 inception period |
| Cash outside trust | $200,884 | $1.33 million at December 31, 2020 |
| Trust assets | $250.01 million | $250.00 million at December 31, 2020 |
| Working capital | Deficit of $1.07 million | Not stated here as a comparable figure |
| Total liabilities | $17.25 million | $23.50 million at December 31, 2020 |
The 2021 net income largely reflects a $7.74 million non-cash gain from the decline in the fair value of warrant liabilities; it does not represent operating profitability. The company reported no operating revenue. Liabilities included $6.90 million of warrant liabilities, an $8.75 million deferred underwriting fee payable upon a completed business combination, and a $544,000 non-interest-bearing sponsor note. The Class A shares subject to possible redemption were presented separately as $250 million of temporary equity.
Changes versus the prior period
General and administrative expenses increased by $2.93 million, primarily due to costs related to the proposed Memic transaction. Net results moved from a loss to income mainly because the warrant fair-value change shifted from an $83,333 loss in the 2020 inception period to a $7.74 million gain in 2021. Cash outside the trust fell from $1.33 million to $200,884, while the trust balance remained approximately $250 million. The 2020 comparison covers only the period from inception, not a full fiscal year.
Outlook, risks, and unusual items
- The company had until December 22, 2022 to complete a business combination; otherwise, it was required to cease operations, redeem public shares from the trust subject to applicable claims and requirements, and liquidate. Warrants would expire worthless if no combination closed.
- Management and the auditor stated that liquidity constraints and the mandatory liquidation deadline raised substantial doubt about the company’s ability to continue as a going concern. The audited financial statements were not adjusted for a possible liquidation.
- The filing reports a material weakness in internal control over financial reporting involving accounting for complex financial instruments. Management concluded that disclosure controls and internal control over financial reporting were not effective at year-end and described remediation efforts.
- After year-end, the sponsor provided $75,000 under a non-interest-bearing note with a maximum principal amount of $400,000. The December 2021 sponsor note matures upon completion of a business combination.
- The proposed Memic transaction also contemplated price-adjustment rights for Memic shareholders, potentially up to 17% of specified post-transaction share measures, and a $76.35 million PIPE, both subject to transaction terms and closing.
- The filing states that the SEC declared Memic’s registration statement effective on February 11, 2022 and that a special meeting was scheduled for “March 9, 2021.” That meeting date appears inconsistent with the filing’s 2022 chronology and should be checked against the definitive proxy and subsequent filings.
- The filing describes the company as a shell company and reports no pending or contemplated litigation known to management.
Important facts for investors to verify
- Confirm the issuer identity: this filing is for MedTech Acquisition Corporation, not TriSalus Life Sciences, Inc.
- Check subsequent filings for the actual status and outcome of the proposed Memic merger, including the meeting date, redemptions, PIPE funding, and any revised transaction terms.
- Review trust-account assets, redemption value, remaining cash outside the trust, sponsor financing, and the deferred underwriting fee when assessing liquidity and transaction funding.
- Evaluate the effect of warrant accounting on reported earnings and the company’s disclosed internal-control material weakness.
- Assess the going-concern warning, December 22, 2022 deadline, and potential creditor claims against trust funds if a transaction failed.